Empowering investors with access to the best research, experts and opportunities.
There usually comes a point in time when a junior explorer gets to a stage in their lifecycle as a pre-production company that requires a strategic partnership in order to take that crucial next step. Far East Gold Ltd (ASX: FEG) has reached that point, and their new strategic investor and major shareholder is perfectly positioned to propel FEG into a new chapter of development opportunities.
The XJO has continued to trade in a sideways channel, with a mixture of positive earnings numbers and U.S. banking sector weakness overnight having an impact.
Every second week we invite a leading fund manager to present at The Insider: Meet the Fund Manager. In August 2023, Datt Capital’s Emanuel Datt selected Global Lithium Resources (ASX: GL1) as one of his favourite stocks, highlighting the company’s…
The gold standard was abandoned long ago, and a large portion of many countries’ gold reserves were sold down with it. The selling got particularly brutal during the 1990s and early 2000’s, where strong economic growth made bullion less attractive and in general just unimportant.
It’s been another strong quarter for Far East Gold Ltd (ASX: FEG), with a raft of assays flooding in from their flagship Woyla Project in Indonesia that continued to show extensive high-grade gold and silver mineralisation throughout the system.
We’ve all heard the story before. Someone gets injured after eating or drinking something at a restaurant and sues the offending restaurant.
BHP’s profits have taken a 37% slump, as the mining giant booked a $US13.4 billion (A$20.9 billion) annual profit for the financial year 2022-23.
In a strategic move to bolster the development plans of VHM Limited (ASX: VHM) for their flagship Goschen Project, the rare-earths developer has appointed three new directors to the board. Each brings a unique skill set that will drive the company through their next chapter as a globally significant producer of the critical minerals that are desperately required for the energy transition.
Prescient Therapeutics (ASX: PTX) had a solid FY23 that has set the stage for a pivotal year to come. Front and centre of the company’s aspirations is commercialising their targeted cell therapies, primarily PTX-100. The announcement of a complete eradication of cancer in two patients has the asset shaping up to be a game changer for Peripheral T-cell lymphoma (PTCL), an area of oncology with a sizable and under-served target market.
A few years ago, it was all about AI. Now, it’s all about generative AI. In fact, the UBS Truth Lab recorded almost 500 companies across 27 sectors making more than 3,500 references to generative AI in earnings calls during the first 5 months of 2023.
The XJO continues to travel in a sideways channel, while Chinese lending figures raised concerns about the health of its economy. New yuan loans in July fell to their lowest levels since 2009, causing Asian markets to fall.
Every second week we invite a leading fund manager to present at The Insider: Meet the Fund Manager. In August 2023, Datt Capital’s Emanuel Datt selected WA1 Resources (ASX: WA1) as one of his favourite stocks, highlighting the company’s world…
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.